Cargando…
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in EGFR mutation positive advanced non-small cell lung cancer (aNSCLC) patients. Generally, they are well-tolerated but skin toxicity is common (45–100% of patients) and may adversely affect quality of life. Pathogenesis of cutaneou...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220808/ https://www.ncbi.nlm.nih.gov/pubmed/34179028 http://dx.doi.org/10.3389/fmed.2021.570921 |
_version_ | 1783711218927665152 |
---|---|
author | Ferro, Alessandra Filoni, Angela Pavan, Alberto Pasello, Giulia Guarneri, Valentina Conte, PierFranco Alaibac, Mauro Bonanno, Laura |
author_facet | Ferro, Alessandra Filoni, Angela Pavan, Alberto Pasello, Giulia Guarneri, Valentina Conte, PierFranco Alaibac, Mauro Bonanno, Laura |
author_sort | Ferro, Alessandra |
collection | PubMed |
description | EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in EGFR mutation positive advanced non-small cell lung cancer (aNSCLC) patients. Generally, they are well-tolerated but skin toxicity is common (45–100% of patients) and may adversely affect quality of life. Pathogenesis of cutaneous side effects is usually linked to EGFR expression in normal cells of the epidermis and not immune-related. Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease and about 40% of SCLE cases are drug related, but no reports are available involving osimertinib. Our report depicts a drug induced-SCLE (DI-SCLE) caused by erlotinib and worsened by osimertinib. The adverse event is characterized by the absence of systemic symptoms. Diagnosis has been performed by skin biopsy and the conditions improved with systemic steroids administration and EGFR-TKIs discontinuation. The report underlines the importance of a complete dermatologic diagnosis of skin lesions induced by EGFR inhibitors, according to symptom severity and timing of improving with standard clinical management. The diagnosis of immune-related skin toxicity in this context affects the treatment and the outcome of skin toxicity and must be taken into account when planning subsequent treatments, potentially including immune checkpoint inhibitors (ICIs). |
format | Online Article Text |
id | pubmed-8220808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82208082021-06-24 Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report Ferro, Alessandra Filoni, Angela Pavan, Alberto Pasello, Giulia Guarneri, Valentina Conte, PierFranco Alaibac, Mauro Bonanno, Laura Front Med (Lausanne) Medicine EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in EGFR mutation positive advanced non-small cell lung cancer (aNSCLC) patients. Generally, they are well-tolerated but skin toxicity is common (45–100% of patients) and may adversely affect quality of life. Pathogenesis of cutaneous side effects is usually linked to EGFR expression in normal cells of the epidermis and not immune-related. Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease and about 40% of SCLE cases are drug related, but no reports are available involving osimertinib. Our report depicts a drug induced-SCLE (DI-SCLE) caused by erlotinib and worsened by osimertinib. The adverse event is characterized by the absence of systemic symptoms. Diagnosis has been performed by skin biopsy and the conditions improved with systemic steroids administration and EGFR-TKIs discontinuation. The report underlines the importance of a complete dermatologic diagnosis of skin lesions induced by EGFR inhibitors, according to symptom severity and timing of improving with standard clinical management. The diagnosis of immune-related skin toxicity in this context affects the treatment and the outcome of skin toxicity and must be taken into account when planning subsequent treatments, potentially including immune checkpoint inhibitors (ICIs). Frontiers Media S.A. 2021-06-04 /pmc/articles/PMC8220808/ /pubmed/34179028 http://dx.doi.org/10.3389/fmed.2021.570921 Text en Copyright © 2021 Ferro, Filoni, Pavan, Pasello, Guarneri, Conte, Alaibac and Bonanno. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Ferro, Alessandra Filoni, Angela Pavan, Alberto Pasello, Giulia Guarneri, Valentina Conte, PierFranco Alaibac, Mauro Bonanno, Laura Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report |
title | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report |
title_full | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report |
title_fullStr | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report |
title_full_unstemmed | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report |
title_short | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report |
title_sort | subacute cutaneous lupus erythematosus-like eruption induced by egfr -tyrosine kinase inhibitor in egfr-mutated non-small cell lung cancer: a case report |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220808/ https://www.ncbi.nlm.nih.gov/pubmed/34179028 http://dx.doi.org/10.3389/fmed.2021.570921 |
work_keys_str_mv | AT ferroalessandra subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT filoniangela subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT pavanalberto subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT pasellogiulia subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT guarnerivalentina subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT contepierfranco subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT alaibacmauro subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport AT bonannolaura subacutecutaneouslupuserythematosuslikeeruptioninducedbyegfrtyrosinekinaseinhibitorinegfrmutatednonsmallcelllungcanceracasereport |